Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04835805 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

A Phase 1 study of Melanoma, sponsored by Genentech.

Active
Registry status
Phase 1
Development phase
65
Enrollment target
17
Study locations

NCT04835805 is a Phase 1 study of Melanoma that is active but no longer recruiting, run by Genentech. The registered enrollment target is 65 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (91% lower). The trial reports 17 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04835805, a Phase 1 study of Melanoma, is active but no longer recruiting, sponsored by Genentech.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
65 participants
Enrollment target
17
Study locations

Study Summary

This study will evaluate the safety, pharmacokinetics, and activity of belvarafenib as a single agent and in combination with either cobimetinib or cobimetinib plus nivolumab in patients with NRAS-mutant advanced melanoma who have received anti-PD-1/PD-L1 therapy.

Conditions Studied

Melanoma

Interventions

  • DRUG Nivolumab
  • DRUG Cobimetinib
  • DRUG Belvarafenib

Study Locations (17)

Other

  • Charité - Universitätsmedizin Berlin - Berlin
  • Universitätsklinikum Hamburg-Eppendorf - Hamburg
  • Klinikum Mannheim GmbH Universitätsklinikum - Mannheim
  • Universitatsklinikum Tubingen - Tübingen
  • Universitätsklinikum Würzburg - Würzburg
  • Asan Medical Center - PPDS - Seoul

California

  • California Pacific Medical Center Research Institute - San Francisco
  • UCSF Helen Diller Family CCC - San Francisco

Ontario

  • Ottawa Hospital Regional Cancer Centre - Ottawa
  • Princess Margaret Hospital - Toronto

Colorado

  • University of Colorado Cancer Center - Aurora

Maryland

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore

Missouri

  • Washington University School of Medicine - St Louis

New York

  • Memorial Sloan Kettering - New York

New South Wales

  • Calvary Mater Newcastle - Waratah

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2021-05-13
Est. Completion 2027-06-30
Phase Phase 1

Sponsor

Genentech

332 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04835805

The ClinicalTrials.gov registry entry for NCT04835805 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (91% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.

NCT04835805 reports 17 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Ontario.

Frequently Asked Questions

What is clinical trial NCT04835805 about?

NCT04835805 is a clinical study titled "A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.". This study will evaluate the safety, pharmacokinetics, and activity of belvarafenib as a single agent and in combination with either cobimetinib or cobimetinib plus nivolumab in patients with NRAS-mutant advanced melanoma who have received anti-PD-1/PD-L1 therapy.

What is the current status of trial NCT04835805?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2021-05-13. Estimated completion is 2027-06-30.

What conditions does trial NCT04835805 study?

This clinical trial studies the following conditions: Melanoma.

What interventions are being tested in trial NCT04835805?

The interventions under investigation include: Nivolumab (DRUG), Cobimetinib (DRUG), Belvarafenib (DRUG).

Who is sponsoring clinical trial NCT04835805?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04835805 being conducted?

This trial has 17 study locations across California, Colorado, Maryland, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Melanoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.